Table 3 Univariate and multivariate analysis of independent risk factors associated to progression after first ipsilateral recurrence

Age (year) at diagnosis

0.031

0.027

 < 40

14 (30.4)

2 (7.4)

ref

ref

 ≥40

32 (69.6)

25 (92.6)

4.940 (1.162–20.998)

5.541 (1.216–25.250)

Breast operation

0.815

 Breast conserving surgery

29 (63.0)

15 (55.6)

ref

 Mastectomy

17 (37.0)

12 (44.4)

1.095 (0.512–2.341)

Axillary operation

0.056

 No

1 (2.2)

0

ref

 SLNB

20 (43.5)

4 (14.8)

3614.374 (0–8.176E114)

 ALND

25 (54.3)

23 (85.2)

13,308.201 (0–3.006E115)

pT

0.017

0.046

 1

32 (69.6)

10 (37.0)

ref

ref

 2

14 (30.4)

17 (63.0)

2.600 (1.184–5.709)

3.255 (1.022–10.363)

pN

0.009

0.110

 0

35 (76.1)

17 (63.0)

ref

ref

 1

8 (17.4)

7 (25.9)

1.382 (0.573–3.335)

0.975 (0.400–2.375)

 2

3 (6.5)

1 (3.7)

0.623 (0.082–4.712)

0.551 (0.061–4.962)

 3

0

2 (7.4)

59.942 (8.156–440.544)

14.851 (1.627–135.571)

Pathologic stage

<0.001

0.022

 I

43 (93.5)

18 (66.7)

ref

ref

 II

3 (6.5)

7 (25.9)

4.038 (1.652–9.871)

2.194 (0.823–5.854)

 III

0

2 (7.4)

80.273 (10.782–597.654)

20.642 (2.569–165.849)

ER status

0.290

 Negative

1 (2.2)

1 (3.7)

ref

 Positive

45 (97.8)

26 (96.3)

0.333 (0.044–2.549)

PR status

0.116

 Negative

8 (17.4)

7 (25.9)

ref

 Positive

38 (82.6)

20 (74.1)

0.498 (0.209–1.188)

HG

0.076

 1

15 (32.6)

3 (11.1)

ref

 2

22 (47.8)

15 (55.6)

2.903 (0.838–10.059)

 3

9 (19.6)

9 (33.3)

3.844 (1.032–14.317)

Ki-67

0.246

 ≤15%

26 (56.5)

12 (44.4)

ref

 > 15

20 (43.5)

15 (55.6)

1.573 (0.732–3.378)

LVI

0.013

0.048

 No

33 (71.7)

11 (40.7)

ref

ref

 Yes

12 (26.1)

16 (59.3)

2.914 (1.346–6.305)

1.959 (0.863–4.447)

 Unknown

1(2.2)

0

Adjuvant chemotherapy

0.307

 No

23 (50.0)

12 (44.4)

ref

 Yes

23 (50.0)

15 (55.6)

1.491 (0.693–3.206)

Adjuvant radiotherapy

0.771

 No

16 (34.8)

12 (44.4)

ref

 Yes

30 (65.2)

15 (55.6)

0.893 (0.418–1.910)

Adjuvant endocrine therapy

0.602

 No

2 (4.3)

1 (3.7)

ref

 Yes

44 (95.7)

26 (96.3)

1.704 (0.230–12.607)

Site of first recurrence

0.150

 Breast

30 (65.2)

10 (37.0)

ref

 Axilla

7 (15.2)

7 (25.9)

2.114 (0.801–5.580)

 Chest wall/skin

7 (15.2)

7 (25.9)

2.037 (0.772–5.377)

 Two or more

2 (4.3)

3 (11.1)

3.840 (1.048–14.070)

Number of recurrence

0.11

 One

44 (95.7)

24 (88.9)

ref

 Two or more

2 (4.3)

3 (11.1)

2.683 (0.801–8.993)

Post-recurrence chemotherapy

0.125

 No

27 (58.7)

11 (40.7)

ref

 Yes

19 (41.3)

16 (59.3)

1.831 (0.846–3.964)

Post-recurrence radiotherapy

0.651

 No

35 (76.1)

21 (77.8)

ref

 Yes

11 (23.9)

6 (22.2)

0.811 (0.327–2.012)

Post-recurrence endocrine therapy

<0.001

<0.001

 No

9 (19.6)

18 (66.7)

ref

ref

 Yes

37 (80.4)

9 (33.3)

0.173 (0.076–0.389)

0.176 (0.070–0.442)